Trisalus Life Sciences (TLSI) closed at $3.67 on October 21, 2026, up 0.3% from the previous close, on volume of 75,717 shares (30-day average 372,229).
Data as of October 21, 2026.
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
Business Wire (Tue, 20-Oct 4:32 PM ET)
Market Chameleon (Wed, 23-Sep 6:31 AM ET)
Market Chameleon (Wed, 23-Sep 3:06 AM ET)
Business Wire (Tue, 22-Sep 4:15 PM ET)
Business Wire (Mon, 31-Aug 4:05 PM ET)
TriSalus Life Sciences Reports Second Quarter 2026 Results
Business Wire (Thu, 6-Aug 4:05 PM ET)
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Business Wire (Wed, 29-Jul 4:05 PM ET)
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Trisalus Life Sciences trades on the NASDAQ stock market under the symbol TLSI.
As of October 22, 2026, TLSI stock price climbed to $3.70 with 25,870 million shares trading.
TLSI has a beta of 2.23, meaning it tends to be more sensitive to market movements. TLSI has a correlation of 0.10 to the broad based SPY ETF.
TLSI has a market cap of $227.83 million. This is considered a Small Cap stock.
Last quarter Trisalus Life Sciences reported $11 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.05.
In the last 3 years, TLSI traded as high as $10.42 and as low as $2.20.
The top ETF exchange traded funds that TLSI belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
TLSI has underperformed the market in the last year with a price return of -28.0% while the SPY ETF gained +14.8%. TLSI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.7% and -12.9%, respectively, while the SPY returned +2.2% and -1.9%, respectively.
TLSI support price is $3.50 and resistance is $3.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLSI shares will trade within this expected range on the day.
